• HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US
  • HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US

Pembrolizumab receives FDA-approval to treat cSCC

July 30, 2020
-
News
-
Posted by seoaccount medivisual
Pembrolizumab-treat-cSCC-admacPembrolizumab-treat-cSCC-admac

On 24 June 2020, the US FDA (United States Food and Drug Administration) granted its approval to pembrolizumab (KEYTRUDA) for patients having recurrent or metastatic cSCC (cutaneous squamous cell carcinoma) that is not curable by surgery or radiation. A multicentre, multi-cohort, non-randomized, open-label trial (KEYNOTE-629) was conducted to explore the efficacy of pembrolizumab.

Notably, those individuals that had previously received therapy with an anti-PD-1 (Programmed cell death protein-1), anti-PD-L1, or anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) antibody and those with autoimmune disease or a medical condition requiring immunosuppression were excluded from this study.

The enrolled participants received an intravenous infusion of 200 mg pembrolizumab every 3 weeks until unacceptable toxicity, disease progression, or a maximum of 24 months. Every six weeks during the first year and every nine weeks during the second year, the tumor status of patients was precisely examined.

The ORR (objective response rate) and response duration as assessed by blinded independent central review according to RECIST (Response Evaluation Criteria in Solid Tumors) guidelines (version 1.1), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ were the primary outcome measures.

The median response duration was not attained (range: 2.7, 13.1+ months) and the ORR was illustrated to be 34%. In patients with cSCC, the occurrence of toxic reactions was found to be comparable to those occurring in patients treated with pembrolizumab as a single agent in other clinical trials.

The major toxic effects linked with pembrolizumab administration are musculoskeletal pain, fatigue, decreased appetite, diarrhea, nausea, pyrexia, cough, rash, constipation, dyspnoea, pain, abdominal pain, and pruritus. Pembrolizumab is also linked with immune-mediated toxic effects such as colitis, pneumonitis, hepatitis, endocrinopathies, skin adverse reactions, and nephritis.

Notably, for managing cSCC, the safety and efficacy of pembrolizumab utilizing a dosage of 400 mg every six weeks were substantially in accordance with the modelling of dose/exposure safety and efficacy relationships, as well as pharmacokinetic data witnessed in patients suffering from melanoma. For managing cSCC, the dose of pembrolizumab is recommended to be 200 mg every 3 weeks or 400 mg every 6 weeks.

Source: US FDA

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma#:~:text=FDA%20approves%20pembrolizumab%20for%20cutaneous%20squamous%20cell%20carcinoma,-Share&text=On%20June%2024%2C%202020%2C%20the,curable%20by%20surgery%20or%20radiation.

Original title of the article FDA approves pembrolizumab for cutaneous squamous cell carcinomaAuthors:

← PREVIOUS POST
XPOVIO received FDA-approval to treat relapsed/refractory diffuse large B-cell lymphoma
NEXT POST →
Study evaluates Infigratinib for Cholangiocarcinoma and FGFR2 fusions

Related News

Other posts that you should not miss.
saffron-as-anti-caner-agent-admac

Future of precious & valuable spice as Anti Cancer Agent

December 8, 2020
-
News

The research and treatment in oncology have always been a great area of interest. The reason behind this is the major impact of this deadly disorder on life …

Read More →
Posted by admin
5 MIN READ
PHESGO-HER2-positive-breast-cancer-admac

FDA approves PHESGO to treat HER2-positive breast cancer

July 22, 2020
-
News

On 29 June 2020, a novel fixed-dose combination of trastuzumab, pertuzumab, and hyaluronidase–zzxf (PHESGO, Genentech, Inc.) for subcutaneous injection to treat HERS-2 (human epidermal growth factor receptor 2) …

Read More →
Posted by seoaccount medivisual
2 MIN READ
cancer-admac

Are red and processed meat cancer risk factors?

December 4, 2020
-
News

Cancer is the second most significant cause of morbidity and mortality in developing countries. It changes globally and is liable to vary with modifications in lifestyle and dietary …

Read More →
Posted by admin
5 MIN READ
Please speak to us:
  • Phone:+91 172 2565161 , +91 172 2565162
  • Email : admac@admacinternational.com
Admac House
SCO 84, Sector 5,
Panchkula (Haryana)
134112 INDIA.
Our aim

At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.

All Rights Reserved. 2016
Powered  by: Admac Oncology
FDA Approves Pembrolizumab to Treat cSCC | Admaconcology